Kolexia
Deniaud-Alexandre Elisabeth
Oncologie radiothérapie
Centre Hospitalier Départemental Vendée
La Roche-sur-Yon, France
38 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Léiomyosarcome Syndrome des jambes sans repos Hormones {{person.topmesh6.name}} {{person.topmesh7.name}} {{person.topmesh8.name}} {{person.topmesh9.name}} {{person.topmesh10.name}}

Industries

Ipsen
8 collaboration(s)
Dernière en 2023
Astellas
6 collaboration(s)
Dernière en 2023
A+A
4 collaboration(s)
Dernière en 2023
IQVIA
2 collaboration(s)
Dernière en 2021

Dernières activités

Vendée : un nouvel accélérateur de particules à l'hôpital ... - Actu
Actu FR   23 septembre 2023
GETUG-AFU 22 Phase II Randomized Trial Evaluating Outcomes of Post-Operative Immediate Salvage Radiation Therapy with or without ADT for Patients with Persistently Elevated PSA Level
A Red Journal Special IssueOligometastasis, Part 2   01 décembre 2022
Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study.
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu   11 mars 2022
Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?
Cancers   09 mars 2020
Late Toxicity and Quality of Life from GETUG-AFU 22 Study: A Multicenter Randomized Phase II Trial Comparing Radiotherapy +/- 6 Months of Degarelix as a Salvage Treatment for Patients with Detectable PSA after Radical Prostatectomy
Proceedings of the Amercian Society for Radiation Oncology 61st Annual Meeting   01 septembre 2019
Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients.
PloS one   09 avril 2018
The acute toxicity results of the GETUG-AFU 22 study: A multicenter randomized phase II trial comparing the efficacy of a short hormone therapy in combination with radiotherapy to radiotherapy alone as a salvage treatment for patients with detectable PSA after radical prostatectomy.
2017 Genitourinary Cancers Symposium   29 mars 2017
{{person.lastact8.name}}
{{person.lastact8.jour}}   {{person.lastact8.date}}
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}